FindTrial
Sign In

To determine factors leading to maternal death in pregnant/delivered women suffering from acute liver injury.

A prospective study to evaluate predictors of adverse maternal outcome in hospitalized pregnant/post-partum women with acute liver injury - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/088954
Enrollment
50
Registered
2025-06-16
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O996- Diseases of the digestive system complicating pregnancy, childbirth and the puerperium

Interventions

Intervention1: Nil: Nil

Sponsors

PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Antenatal or postnatal patients suffering from acute liver injury with liver transaminases raised to more than 5 times the normal value and presence of coagulopathy with INR more than 1.5. 2. Women willing to participate

Exclusion criteria

Exclusion criteria: 1. Women with chronic liver disease or symptom duration more than 4 weeks. 2. Women on anti-coagulant drugs. 3. Women more than 42 days post partum. 4. Women not willing to participate

Design outcomes

Primary

MeasureTime frame
To determine predictors of severe maternal outcome in women admitted with acute liver injury in pregnant and postnatal patients.Timepoint: 1 year 3 months—

Secondary

MeasureTime frame
To identify clinical spectrum of ALI in pregnancy and post-partum. Timepoint: 1 year 3 months;To determine maternal and fetal outcome. Timepoint: 1 year 3 months;To correlate the maternal outcome with the three predictive models available for predicting mortality in ALI patientsTimepoint: 1 year 3 months—

Countries

India

Contacts

Public ContactAashima Arora

PGIMER, CHANDIGARH

aashicool84@gmail.com9915501844

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026